Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models
- Author:
Manisha TAYA
1
;
Xiaonan HOU
;
Jennifer T. VENERIS
;
Nina KAZI
;
Melissa C. LARSON
;
Matthew J. MAURER
;
Ethan P. HEINZEN
;
Hao CHEN
;
Ricardo LASTRA
;
Ann L. OBERG
;
S. John WEROHA
;
Gini F. FLEMING
;
Suzanne D. CONZEN
Author Information
- Publication Type:Original Article
- From:Journal of Gynecologic Oncology 2025;36(1):e4-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:In ovarian cancer (OvCa), tumor cell high glucocorticoid receptor (GR) has been associated with poor patient prognosis. In vitro, GR activation inhibits chemotherapyinduced OvCa cell death in association with transcriptional upregulation of genes encoding anti-apoptotic proteins. A recent randomized phase II study demonstrated improvement in progression-free survival (PFS) for heavily pre-treated OvCa patients randomized to receive therapy with a selective GR modulator (SGRM) plus chemotherapy compared to chemotherapy alone. We hypothesized that SGRM therapy would improve carboplatin response in OvCa patient-derived xenograft (PDX).
Methods:Six high-grade serous (HGS) OvCa PDX models expressing GR mRNA (NR3C1) and protein were treated with chemotherapy +/− SGRM. Tumor size was measured longitudinally by peritoneal transcutaneous ultrasonography.
Results:One of the 6 GR-positive PDX models showed a significant improvement in PFS with the addition of a SGRM. Interestingly, the single model with an improved PFS was least carboplatin sensitive. Possible explanations for the modest SGRM activity include the high carboplatin sensitivity of 5 of the PDX tumors and the potential that SGRMs activate the tumor invasive immune cells in patients (absent from immunocompromised mice). The level of tumor GR protein expression alone appears insufficient for predicting SGRM response.
Conclusion:The significant improvement in PFS shown in 1 of the 6 models after treatment with a SGRM plus chemotherapy underscores the need to determine predictive biomarkers for SGRM therapy in HGS OvCa and to better identify patient subgroups that are most likely to benefit from adding GR modulation to chemotherapy.
